• Time of issue:2019-12-06 21:40

(Summary description) Recently, the State Intellectual Property Office issued the "2019 National Intellectual Property Advantage Demonstration Enterprise Review and Re-inspection Results Announcement". Joincare Pharmaceutical Group Co., Ltd. (hereinafter referred to as "Healthcare Pharmaceutical Group") relies on its excellent independent innovation capabilities and A good intellectual property construction management system has passed the rigorous review by the expert group, and successfully won the highest honor awarded by the state for the creation, use, protection, and management of corporate intellectual property rights-the "2019 National Intellectual Property Demonstration Enterprise". It is reported that among the 274 national intellectual property demonstration enterprises in the country this time, only 4 are recommended by Shenzhen Intellectual Property Office, namely, Joincare Pharmaceutical Group, DJI Innovation, Hanyu Pharmaceutical and China Construction Steel. All are industry leaders. It is worth mentioning that, Shenzhen Haibin Pharmaceutical Co., Ltd., a subsidiary of Joincare Pharmaceutical Group, was also awarded the "National Intellectual Property Advantage Enterprise". The two important awards in one fell swoop are that Joincare Pharmaceutical Group always attaches importance to independent research and development of technology, Another fruit of the in-depth implementation of the intellectual property strategy. (The picture comes from the official website of the State Intellectual Property Office) It is reported that in order to implement the spirit of the "National Intellectual Property Strategy Outline" and the "National Patent Business Development Strategy (2011-2020)", to accelerate the formation of a group of backbone enterprises with independent intellectual property rights and well-known brands and strong international competitiveness. The "Notice on Carrying out the Cultivation of National Intellectual Property Advantage Enterprises and Model Enterprises" (Guo Zhi Fa Guan Zi [2013] No. 36) requires that the State Intellectual Property Office assesses national intellectual property model enterprises from 2013. The award of this honor is not only the highest honor awarded by the state to the creation, application, protection, management and other aspects of enterprise intellectual property rights, but also the highest evaluation given by the state to enterprise intellectual property management work. The enterprises that have passed the review are regarded as the leaders of regional intellectual property development Sheep will provide strong support for the development of intellectual property rights. (The picture comes from the official website of the State Intellectual Property Office) Over the years, Joincare Pharmaceutical Group has persisted in implementing the "Enterprise Intellectual Property Management Regulations", established a solid and complete intellectual property management system, attaches great importance to the research and development and innovation of pharmaceutical technology, and has successively obtained a number of intellectual property rights. At the same time, relying on its strength and experience in the field of general health, the company continues to develop pharmaceutical technology with independent intellectual property rights. It has developed from a well-known health care product company to a large health pharmaceutical group with strong comprehensive strength in China. Its business covers chemical preparations, Numerous sectors including APIs, Chinese medicines, health products, OTC, and diagnostic reagents. Joincare Pharmaceutical Group and Shenzhen Haibin Pharmaceutical Co., Ltd. were awarded the "2019 National Intellectual Property Demonstration Enterprise" and "National Intellectual Property Advantage Enterprise" respectively. They are authoritative institutions for the group's independent research and development capabilities, intellectual property protection capabilities and future markets. The best affirmation of development potential also marks that Joincare Pharmaceutical Group has reached a new level in the management of intellectual property rights. Relevant leaders of the group stated that in the future, the company will continue to increase investment in scientific research, focus on core technology research and development, and improve related intellectual property protection mechanisms, strengthen the transformation of scientific research results, while consolidating and enhancing its core competitive advantages, it will help promote the Guangdong-Hong Kong-Macao University Innovative development in the Bay Area.